MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

ANI Pharmaceuticals Company Profile (NASDAQ:ANIP)

Consensus Ratings for ANI Pharmaceuticals (NASDAQ:ANIP) (?)
Ratings Breakdown: 1 Hold Rating(s), 3 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $58.40 (3.95% upside)

Analysts' Ratings History for ANI Pharmaceuticals (NASDAQ:ANIP)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016Raymond JamesInitiated CoverageStrong-Buy$68.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016GuggenheimReiterated RatingBuy$55.00 -> $65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/24/2016Standpoint ResearchDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016OppenheimerReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2015Roth CapitalReiterated RatingBuy$60.00 -> $56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for ANI Pharmaceuticals (NASDAQ:ANIP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/5/2016Q116$0.64$0.76$21.03 million$20.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q415$0.60$0.52$18.13 million$18.04 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315$0.63$0.80$21.37 million$20.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215$0.54$0.31$20.30 million$19.52 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q115$0.56$0.57$19.86 million$18.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2015Q414$0.58$0.67$17.98 million$21.04 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014Q314$0.46$0.66$14.60 million$17.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2014Q214$0.01($0.21)$7.95 million$6.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2014Q115$0.32$0.33$11.40 million$10.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q414$0.35$5.32 million$10.53 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013$0.16ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for ANI Pharmaceuticals (NASDAQ:ANIP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.24$0.24$0.24
Q2 20161$0.36$0.36$0.36
Q3 20161$0.44$0.44$0.44
Q4 20161$0.40$0.40$0.40
(Data provided by Zacks Investment Research)
Dividend History for ANI Pharmaceuticals (NASDAQ:ANIP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for ANI Pharmaceuticals (NASDAQ:ANIP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/18/2015James G MarkenVPSell3,500$43.26$151,410.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2015Arthur PrzybylCEOBuy2,500$40.95$102,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015James G MarkenVPSell15,000$66.50$997,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Ross J ManganoDirectorBuy3,000$27.49$82,470.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2014Arthur PrzybylCEOBuy1,000$26.50$26,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014James G MarkenVPSell5,000$34.28$171,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2014Tracy MarshbanksDirectorSell1,381$30.02$41,457.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2014Ross ManganoDirectorBuy2,000$30.38$60,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014Tracy MarshbanksDirectorSell21,767$31.42$683,919.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2014Meridian Venture Partners Ii Lmajor shareholderSell20,922$32.12$672,014.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2014Tracy MarshbanksDirectorSell25,358$33.68$854,057.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2014Meridian Venture Partners Ii Lmajor shareholderSell60,540$34.07$2,062,597.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2014Meridian Venture Partners Ii Lmajor shareholderSell87,723$32.48$2,849,243.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2013Ross J ManganoDirectorBuy9,000$11.27$101,430.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2013Ross J ManganoDirectorBuy10,000$7.47$74,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for ANI Pharmaceuticals (NASDAQ:ANIP)
DateHeadline
06/30/16 10:21 AMHorizon (HZNP) Stock Up on Ravicti Label Expansion Filing
06/29/16 07:38 PMShort Data Recap for: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Engelwood Daily
06/29/16 02:29 PMIs ANI Pharmaceuticals Inc a Buy? The Stock Rises Again - Press Telegraph
06/29/16 10:43 AMANI Pharmaceuticals Inc. (ANIP) Jumps 8.47% on June 28 - Equities.com
06/28/16 07:52 PMA Reversal for ANI Pharmaceuticals Inc Is Not Near. The Stock Rises Again - Press Telegraph
06/28/16 07:52 PMANI Pharma (ANIP) Announces Commercial Launch of HPC USP 250mg/mL in 5mL Vials - StreetInsider.com
06/28/16 07:46 AMGW Pharmaceuticals Stock Up on Positive Epidiolex Data
06/28/16 07:31 AMANI Pharmaceuticals Announces Launch of Hydroxyprogesterone Caproate Injection USP, 250mg/mL - [at noodls] - BAUDETTE, Minnesota (June 28, 2016) - ANI Pharmaceuticals, Inc. ('ANI') (Nasdaq: ANIP) today announced the commercial launch of Hydroxyprogesterone Caproate Injection ('HPC') USP 250mg/mL in 5mL vials. ...
06/27/16 07:15 AMStrong Sell Calls Recommendations For ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) At 0 - Investor Newswire
06/26/16 02:26 PMANI Pharmaceuticals, Inc. (ANIP) Broker Price Targets For The Coming Week - Fiscal Standard
06/24/16 11:17 AMGenmab/Novartis' Arzerra Gets Unfavorable CHMP Opinion -
06/24/16 09:10 AMANI Pharmaceuticals Inc. (ANIP) Jumps 6.59% on June 23 - Equities.com
06/23/16 09:54 PMRaymond James reported on (NASDAQ:ANIP) ANI Pharmaceuticals, keeping its target price to $0 earlier today
06/22/16 07:18 AMANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) Stock Momentum Hits Strength - CML News
06/21/16 02:28 PMANI Pharmaceuticals, Inc. (ANIP) Current Analyst Ratings - Fiscal Standard
06/20/16 02:29 PMWatch List: ConocoPhillips (NYSE:COP), ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), Alcoa Inc. (NYSE:AA), Gold ... - KC Register
06/15/16 07:19 AMUS FDA approves ANI Pharma's oxcarbazepine tablets
06/14/16 02:30 PMANI Pharmaceuticals Inc (NASDAQ:ANIP) Receives FDA Approval for Oxcarbazepine - Small Cap Exclusive (press release)
06/14/16 07:16 AMANI Pharmaceuticals Announces Launch of Oxycodone Capsules, 5mg
06/13/16 10:35 AMBRIEF-ANI Pharmaceuticals announces FDA approval of oxcarbazepine tablets
06/13/16 10:35 AMANI Pharma Launches Oxycodone Capsules; FDA Approves Oxcarbazepine Tablets
06/13/16 10:35 AMANI Pharmaceuticals Announces FDA Approval of Oxcarbazepine Tablets
06/13/16 08:49 AMANI Pharmaceuticals Gets FDA Approval For Oxcarbazepine Tablets -
06/08/16 10:56 AMANI PHARMACEUTICALS INC. (NASDAQ:ANIP) Financial Condition Compared to S&P 500 - CML News
06/07/16 10:51 AMAstraZeneca Presents Tagrisso Leptomeningeal Disease Data -
06/07/16 10:49 AMAlexion's Soliris Misses Phase III Primary Efficacy Endpoint -
06/06/16 09:52 AMPfizer (PFE) Presents Data on Utomilumab for Solid Tumors -
06/05/16 07:49 PMNext Weeks Broker Price Targets For ANI Pharmaceuticals, Inc. (ANIP) - Share Trading News
06/05/16 02:31 PMAre Analysts Bearish ANI Pharmaceuticals Inc (NASDAQ:ANIP) After Last Week? - HNN
06/03/16 11:00 AMHealthcare Value Capital LLC Increased Ani Pharmaceuticals INC (NASDAQ:ANIP) by $12.21 Million as Shares ... - CCH Daily News
06/03/16 11:00 AMANI Pharmaceuticals, Inc. (ANIP) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News
06/01/16 10:55 AMStandpoint Research Downgrades ANI Pharmaceuticals Inc to Hold - Trade Calls - Standpoint Research Downgrades ANI Pharmaceuticals Inc to HoldTrade CallsBrokerage firm Standpoint Research Downgrades its rating on ANI Pharmaceuticals Inc(NASDAQ:ANIP). The shares have been rated Hold. Previously, the analysts had a Buy rating on the shares. The rating by Standpoint Research was issued on May 24, ...Buy, Sell Or Hold Rating For ANI Pharmaceuticals, Inc. (ANIP)?Share Trading NewsStock Trending Up: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)The Postall 4 news articles »
05/31/16 02:33 PMGilead's (GILD) New HCV Drug Epclusa Wins CHMP Backing - Gilead is a Zacks Rank #3 (Hold) stock. A couple of better-ranked stocks in the health care sector are ANI Pharmaceuticals, Inc. ANIP and Retrophin, Inc. RTRX – each sporting a Zacks Rank #1 (Strong Buy).
05/27/16 08:34 PMAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Analysts Recommendations and Insider Trading - A better-ranked biomedical stock is ANI Pharmaceuticals, Inc. The businesses 50 day moving average is 63.09 and its 200 day moving average is 74.3. Analyst consensus one year target price is registered at $16.33. In the last reported results, the company ...
05/27/16 08:34 PMANI PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holders (form 8-K) - Item 5.07. Submission of Matters to a Vote of Security Holders. On May 25, 2016, ANI Pharmaceuticals, Inc. (the "Company") held its 2016 Annual Meeting of Stockholders. The following matters, all of which were set forth in the Company's proxy statement for ...
05/27/16 08:15 AMWill ANI Pharmaceuticals (ANIP) Continue to Surge Higher? -
05/26/16 03:32 PMANI PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/25/16 07:14 PMNotable Wednesday Option Activity: ASNA, ANIP, CVX - Today's Most Active Call & Put Options of the S&P 500 » ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) saw options trading volume of 967 contracts, representing approximately 96,700 underlying shares or approximately 48% of ANIP's average daily trading volume ...
05/25/16 01:44 AMANI Pharmaceuticals : Announces Appointment of Mark J. Ginski Ph.D as Vice President Corticotropin Product Development - BAUDETTE, Minn., May 23, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the appointment of Mark Ginski Ph.D as Vice President Corticotropin Product Development, effective May 23, 2016. Mark J. Ginski is an ...
05/24/16 10:03 AMANI Pharma downgraded by Standpoint Research -
05/23/16 07:30 AMANI Announces Appointment of Mark J. Ginski Ph.D as Vice President Corticotropin Product Development - [PR Newswire] - BAUDETTE, Minn., May 23, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the appointment of Mark Ginski Ph.D as Vice President Corticotropin Product Development, ...
05/20/16 07:23 PMANI Pharmaceuticals, Inc. (NASDAQ:ANIP) One-Year Price Projection At $52 - Investor Newswire - ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) One-Year Price Projection At $52Investor NewswireSell-side analysts are certain on the prospect of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) stock. As of 2016-05-19, the stock ABR stands at 1. This type of rating states that whenever a stock has a score of 5, investors should avoid investing in such ...and more »
05/18/16 07:46 PMANI Pharmaceuticals, Inc. (ANIP) Updated Broker Price Targets - Share Trading News - ANI Pharmaceuticals, Inc. (ANIP) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of ANI Pharmaceuticals, Inc. (ANIP). The latest reports which are currently in issue on Wednesday 18th of May state 0 analysts have a rating of “strong buy”, 0 analysts ...and more »
05/18/16 08:52 AMANI Pharmaceuticals to Present at the UBS Global Healthcare Conference - [at noodls] - BAUDETTE, Minnesota (May 18, 2016) - ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that it will present on May 23, 2016 at the UBS Global Healthcare Conference at the Grand Hyatt in New York ...
05/18/16 05:02 AMSouth Africa's Aspen Pharmacare signs U.S. supply deal with ANI -
05/17/16 06:58 PMANI Pharma (ANIP) Enters $30M Credit Facility - StreetInsider.com - ANI Pharma (ANIP) Enters $30M Credit FacilityStreetInsider.comOn May 12, 2016, ANI Pharmaceuticals, Inc. (the “Company” or “ANI”) entered into a credit agreement with Citizens Business Capital, a division of Citizens Asset Finance, Inc. (the “Citizens Agreement”). The Citizens Agreement provides for a $30.0 ...
05/17/16 03:33 PMANI PHARMACEUTICALS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-B -
05/17/16 09:42 AMANI Pharmaceuticals Enters Into Exclusive Distribution and Supply Agreement for Hydroxyprogesterone Caproate Injection USP - [at noodls] - BAUDETTE, Minnesota (May 17, 2016) - ANI Pharmaceuticals, Inc. ('ANI') (Nasdaq: ANIP) today announced the signing of an exclusive distribution and supply agreement with Aspen Global Incorporated for Hydroxyprogesterone ...
05/16/16 11:12 AMANI Pharmaceuticals Launches Authorized Generic of Rowasa® Enema 4g/60mL - [at noodls] - BAUDETTE, Minnesota (May 16, 2016) - ANI Pharmaceuticals, Inc. ('ANI') (Nasdaq: ANIP) today announced the commercial launch of authorized generic Rowasa® (mesalamine) rectal suspension enema 4g/60ml in ...
05/13/16 08:05 PMANI Pharmaceuticals, Inc. (NASDAQ:ANIP) One-Year Mean Price Target At $52 - Investor Newswire - ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) One-Year Mean Price Target At $52Investor NewswireSell-side analysts are confident on the future outlook of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) stock. As of 2016-05-12, the stock has an ABR of 1 rating, where number 5 denotes a Strong Sell and 1 Strong Buy. The ABR is reached on the basis of ...and more »
About ANI Pharmaceuticals

ANI Pharmaceuticals logoANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company's focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations. Its generic products include Esterified Estrogen with Methyltestosterone, Etodolac, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup, Nimodipine, Opium Tincture, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Lithobid, Reglan and Vancocin. It has over two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products. Its two facilities have a combined manufacturing, packaging and laboratory capacity totaling approximately 173,000 square feet.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ANIP
  • CUSIP:
Key Metrics:
  • Previous Close: $56.18
  • 50 Day Moving Average: $52.17
  • 200 Day Moving Average: $41.73
  • P/E Ratio: 52.21
  • P/E Growth: 1.04
  • Market Cap: $638.44M
  • Current Quarter EPS Consensus Estimate: $3.67 EPS
Additional Links:
ANI Pharmaceuticals (NASDAQ:ANIP) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha